DK1735027T3 - Stabiliserede, biologisk nedbrydelige neurotoksinimplantater - Google Patents

Stabiliserede, biologisk nedbrydelige neurotoksinimplantater

Info

Publication number
DK1735027T3
DK1735027T3 DK05821172.3T DK05821172T DK1735027T3 DK 1735027 T3 DK1735027 T3 DK 1735027T3 DK 05821172 T DK05821172 T DK 05821172T DK 1735027 T3 DK1735027 T3 DK 1735027T3
Authority
DK
Denmark
Prior art keywords
stabilized
biodegradable neurotoxin
implants
neurotoxin implants
biodegradable
Prior art date
Application number
DK05821172.3T
Other languages
English (en)
Inventor
Patrick Hughes
Orest Olejnik
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1735027T3 publication Critical patent/DK1735027T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK05821172.3T 2004-04-15 2005-04-08 Stabiliserede, biologisk nedbrydelige neurotoksinimplantater DK1735027T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/826,441 US7691381B2 (en) 2004-04-15 2004-04-15 Stabilized biodegradable neurotoxin implants
PCT/US2005/012121 WO2006036202A2 (en) 2004-04-15 2005-04-08 Stabilized biodegradable neurotoxin implants

Publications (1)

Publication Number Publication Date
DK1735027T3 true DK1735027T3 (da) 2012-10-01

Family

ID=35096537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05821172.3T DK1735027T3 (da) 2004-04-15 2005-04-08 Stabiliserede, biologisk nedbrydelige neurotoksinimplantater

Country Status (7)

Country Link
US (3) US7691381B2 (da)
EP (1) EP1735027B1 (da)
AU (1) AU2005290334B8 (da)
CA (1) CA2563399C (da)
DK (1) DK1735027T3 (da)
ES (1) ES2389912T3 (da)
WO (1) WO2006036202A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2002007773A2 (en) * 2000-07-21 2002-01-31 Essentia Biosystems, Inc. Multi-component biological transport systems
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP5095388B2 (ja) 2004-03-03 2012-12-12 ルバンス セラピュティックス インク． ボツリヌストキシンの局所適用及び経皮送達のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
ES2362301T3 (es) * 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
BRPI0618753A2 (pt) * 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP3047860A1 (en) 2006-07-20 2016-07-27 OrbusNeich Medical, Inc. Bioabsorbable polymeric composition for a medical device
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
CN101631513B (zh) 2006-10-20 2013-06-05 奥巴斯尼茨医学公司 可生物吸收的聚合物组合物和医疗设备
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
MX2009007070A (es) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Moleculas de transporte que utilizan los polipeptidos hiv-tat de secuencia inversa.
JP2010514781A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
KR102552356B1 (ko) 2016-08-26 2023-07-07 에스케이 조인트 벤처스 보툴리눔 독소의 효능 증대를 위한 생분해성 폴리머 제제
CN115531300A (zh) * 2022-08-14 2022-12-30 中国人民解放军海军军医大学 河豚毒素注射型植入剂及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (da) 1962-07-11
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US5741329A (en) * 1994-12-21 1998-04-21 Board Of Regents, The University Of Texas System Method of controlling the pH in the vicinity of biodegradable implants
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
EP0885014B1 (en) * 1996-03-05 2002-10-23 Robert Gurny Pharmaceutical compositions containing buffered ortho ester polymers
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK1398038T4 (da) 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6525016B2 (en) 2001-01-16 2003-02-25 Goldschmidt Chemical Corporation Blend of imidazolinium quat and amido amine quat for use in fabric softeners with premium softening, high-viscosity at low-solids and non-yellowing properties
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants

Also Published As

Publication number Publication date
ES2389912T3 (es) 2012-11-02
CA2563399C (en) 2013-05-28
US8007828B2 (en) 2011-08-30
US8501187B2 (en) 2013-08-06
WO2006036202A2 (en) 2006-04-06
US20100068244A1 (en) 2010-03-18
WO2006036202A3 (en) 2006-07-06
AU2005290334B8 (en) 2012-04-12
AU2005290334B2 (en) 2011-08-25
EP1735027A2 (en) 2006-12-27
EP1735027B1 (en) 2012-06-27
US20120065141A1 (en) 2012-03-15
AU2005290334A1 (en) 2006-04-06
US7691381B2 (en) 2010-04-06
US20050232966A1 (en) 2005-10-20
CA2563399A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
DK1735027T3 (da) Stabiliserede, biologisk nedbrydelige neurotoksinimplantater
NL300935I2 (nl) guselkumab.
NL1028967A1 (nl) 4-Fenylamino-chinazoline-6-yl-amiden.
NO20051522D0 (no) Kabelskjotbeskytter.
DE602005022897D1 (de) Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
NO20053161D0 (no) Mikrobedrepende sammensetning.
NL1030713A1 (nl) Macroliden.
NO20053210D0 (no) Linneslakkompensator.
NO20051199L (no) Rorhandteringsutstyr.
NO20052746D0 (no) Avlopsenhet.
NO20053362L (no) Syklofuge.
NO20041374D0 (no) Bolgekraftverk.
NO20052482D0 (no) Redningskokong.
NO20040762L (no) Stromskinne.
NL1028622A1 (nl) Stelwig.
FR2894782B1 (fr) Implant capillaire
ES1057865Y (es) Desatascador de desagues.
NL1025196A1 (nl) Hark-Zeef-Vork.
ES1057247Y (es) Madriguera artificial.
ITMO20050041A1 (it) Siepe artificale.
ES1057217Y (es) Canape elevable.
ES1057922Y (es) Vitrina frigorifica polivalente.
ES1057779Y (es) Tenso-papelera.
ES1059191Y (es) Candelero tritubular.
ES1058195Y (es) Expositor -botellero.